Location History:
- Yorktown Heights, NY (US) (1983)
- Kankakee, IL (US) (1987 - 1989)
Company Filing History:
2 out of 89 
2 out of 109 Years Active: 1983-1989
Title: Innovator of Peptides: The Contributions of Everett Flanigan
Introduction: Everett Flanigan, an accomplished inventor based in Kankakee, Illinois, has made significant strides in the field of peptide innovations. With a total of four patents to his name, he has focused his research on the synthesis and application of hypocalcemic peptides, which hold promise for various medical applications.
Latest Patents: Flanigan's most recent patents delve into the chemical structure and formulations of peptides, particularly targeting biological activities akin to known calcitonins. His patent on "Analogs of [1,7-di-alanine, des-19-leucine]calcitonin" outlines the creation of new hypocalcemic peptides featuring specific acyl groups and amino acids. These peptides, such as those that do not include leucine in position 19, glutamine in position 20, threonine in position 21, and tyrosine in position 22, highlight innovative approaches to peptide design. Additionally, he has developed resin peptides that can be converted into biologically active peptides.
Career Highlights: Throughout his career, Flanigan has worked with reputable pharmaceutical companies, including Armour Pharmaceutical Company and Rorer Pharmaceutical Corporation. His work at these organizations has underscored his role in pioneering peptide research and contributing to advancements in pharmaceutical sciences.
Collaborations: Collaboration has been a key aspect of Flanigan's work. Notable colleagues such as Ronald C. Orlowski and Jay K. Seyler have partnered with him on various projects. These collaborations have facilitated meaningful contributions to the field and expanded the impact of their research.
Conclusion: Everett Flanigan's innovative work in the development of peptide formulations places him among the prominent inventors in his field. With a strong portfolio of patents and collaborations with esteemed colleagues, he continues to influence the landscape of pharmaceutical research and peptide technology, paving the way for future advancements.